JP2015508903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508903A5 JP2015508903A5 JP2014559890A JP2014559890A JP2015508903A5 JP 2015508903 A5 JP2015508903 A5 JP 2015508903A5 JP 2014559890 A JP2014559890 A JP 2014559890A JP 2014559890 A JP2014559890 A JP 2014559890A JP 2015508903 A5 JP2015508903 A5 JP 2015508903A5
- Authority
- JP
- Japan
- Prior art keywords
- psma
- imaging
- measurement
- prostate cancer
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 63
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 45
- 238000003384 imaging method Methods 0.000 claims description 36
- 238000005259 measurement Methods 0.000 claims description 31
- 206010060862 Prostate cancer Diseases 0.000 claims description 28
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 28
- 238000002600 positron emission tomography Methods 0.000 claims description 18
- 238000011275 oncology therapy Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 230000002280 anti-androgenic effect Effects 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 8
- 239000000051 antiandrogen Substances 0.000 claims description 8
- 238000002591 computed tomography Methods 0.000 claims description 7
- 108091023037 Aptamer Proteins 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 238000012634 optical imaging Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 239000003098 androgen Substances 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 201000007676 prostate small cell carcinoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000006870 function Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261604039P | 2012-02-28 | 2012-02-28 | |
| US61/604,039 | 2012-02-28 | ||
| PCT/US2013/000051 WO2013130177A1 (en) | 2012-02-28 | 2013-02-27 | Psma as a biomarker for androgen activity in prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015508903A JP2015508903A (ja) | 2015-03-23 |
| JP2015508903A5 true JP2015508903A5 (enExample) | 2016-04-14 |
Family
ID=49083148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014559890A Pending JP2015508903A (ja) | 2012-02-28 | 2013-02-27 | 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130315830A1 (enExample) |
| EP (1) | EP2819704A4 (enExample) |
| JP (1) | JP2015508903A (enExample) |
| CA (1) | CA2865774A1 (enExample) |
| HK (1) | HK1202256A1 (enExample) |
| WO (1) | WO2013130177A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6815196B2 (ja) | 2013-03-13 | 2021-01-20 | イマジナブ、 インコーポレイテッド | Ｃｄ８に対する抗原結合性構築物 |
| KR20250008141A (ko) | 2015-08-07 | 2025-01-14 | 이미지냅 인코포레이티드 | 분자를 표적화하기 위한 항원 결합 구조체 |
| CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| CA3056261A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| CN116271117A (zh) * | 2018-09-28 | 2023-06-23 | 伊麦吉纳博公司 | Cd8成像构建体及其使用方法 |
| EP4253957A4 (en) * | 2020-11-24 | 2024-11-06 | Korea Institute of Science and Technology | BIOMARKERS FOR THE DIAGNOSIS OF PROSTATE CANCER, COMBINATION THEREOF AND USE THEREOF |
| EP4267969A4 (en) * | 2020-12-22 | 2025-02-12 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF PROSTATE CANCER |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098885A1 (en) * | 2001-02-07 | 2002-12-12 | Beth Israel Deaconess Medical Center | Modified psma ligands and uses related thereto |
| AU2007227195A1 (en) * | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and Ly6 E: targets for cancer diagnosis and therapy |
| WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| US20100047166A1 (en) * | 2008-08-20 | 2010-02-25 | Kanner Steven B | Antibodies and related molecules that bind to 58p1d12 proteins |
| EP3495000A1 (en) * | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| PL3222617T3 (pl) * | 2009-03-19 | 2023-01-02 | The Johns Hopkins University | Związki do kierunkowania w psma i ich zastosowania |
| US8674172B2 (en) * | 2009-04-14 | 2014-03-18 | Institut Gustave Roussy | Prostate cancer cell lines and their use in screening method |
| US20130225541A1 (en) * | 2012-02-24 | 2013-08-29 | Cornell University | Elevated PSMA Identifies Lethal Prostate Cancers |
-
2013
- 2013-02-27 HK HK15102796.5A patent/HK1202256A1/xx unknown
- 2013-02-27 JP JP2014559890A patent/JP2015508903A/ja active Pending
- 2013-02-27 EP EP13754565.3A patent/EP2819704A4/en not_active Withdrawn
- 2013-02-27 US US13/778,306 patent/US20130315830A1/en not_active Abandoned
- 2013-02-27 CA CA2865774A patent/CA2865774A1/en not_active Abandoned
- 2013-02-27 WO PCT/US2013/000051 patent/WO2013130177A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Avril et al. | Monitoring response to treatment in patients utilizing PET | |
| Ellingson et al. | Pros and cons of current brain tumor imaging | |
| Czernin et al. | PET/CT in oncology: current status and perspectives | |
| Wang et al. | 18F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials | |
| Gerstner et al. | Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib | |
| Ascierto et al. | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | |
| Hodgson | Late effects in the era of modern therapy for Hodgkin lymphoma | |
| Chow et al. | Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma | |
| Alexiou et al. | Comparison of diffusion tensor, dynamic susceptibility contrast MRI and 99mTc-Tetrofosmin brain SPECT for the detection of recurrent high-grade glioma | |
| Berg et al. | Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer | |
| Di Ianni et al. | Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats | |
| Gong et al. | A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel | |
| O’Sullivan et al. | ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment | |
| Townsend et al. | Selective internal radiation therapy for liver metastases from colorectal cancer | |
| Miyatake et al. | Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas | |
| Gordon et al. | Hyperpolarized 13C metabolic MRI of patients with pancreatic ductal adenocarcinoma | |
| Ammari et al. | Radiological evaluation of response to treatment: application to metastatic renal cancers receiving anti-angiogenic treatment | |
| JP2015502339A5 (enExample) | ||
| Nguyen et al. | Revolutionizing brain tumor care: Emerging technologies and strategies | |
| Yavuz et al. | Factors affecting survival in glioblastoma patients below and above 65 years of age: A retrospective observational study | |
| JP2016515141A5 (enExample) | ||
| Khayal et al. | Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme | |
| Tong et al. | Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer | |
| US20160370379A1 (en) | Blood-based biomarker for cancer | |
| Chang et al. | Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma |